Hancock Mark sold $614K of PACS

Hancock Mark sold 13,628 shares of PACS Group, Inc. (PACS) at an average of $45.04 ($45.04–$45.05, $0.61M total) across 2 trades over 2026-07-14 to 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hancock Mark
Published Jul 16, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PACS
Neutral
high confidence
Mentioned
$PACS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSNeutralLow
01

Why it matters

The disclosed fact is the size, timing, and pricing range of the insider sale, plus confirmation it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Insider selling can influence short-term sentiment, but 10b5-1 pre-arrangement usually reduces interpretive weight.

03

What to watch

Traders may also check whether other insiders filed concurrent transactions or whether the company has upcoming catalysts (earnings, guidance) not mentioned here.

Relevance 4/10Novelty 3/10Timing: after-hours, SEC Form 4 filed 2026-07-16

Background

The article is a primary-source SEC Form 4 insider transaction for PACS Group, Inc.

Company-level read

Ticker impact

$PACSNeutralHigh confidence
Context

PACS Group director and 10% owner Hancock Mark sold 13,628 shares in open-market trades at about $45.04, per Form 4 filed today.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing specifies a Rule 10b5-1 pre-arranged plan and an open-market sale, with no accompanying new company-specific operational or financial disclosure.

Market effects

No clear sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • PACS Group, Inc.

    Company whose director/10% owner filed the Form 4 insider sale.

  • Hancock Mark

    Director and 10% owner who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PACSMedAI 8/10

What PACS Group (PACS) Said on Its Q3 Earnings Call

PACS Group reported 196 mature, 90 ramping, and 35 new skilled nursing facilities with occupancy ranging from 76.2% to 93.1%. The company acquired 32 Florida and 10 Texas skilled nursing operations post-quarter. PACS raised its 2026 revenue outlook to $5.95B-$6.05B and adjusted EBITDA to $685M-$695M, citing strength in existing operations and new acquisitions. Operating cash flow was $583.1M for the first nine months of 2026, with $707.4M in available liquidity.

$PACSHighAI 8/10

PACS Group Inc (PACS) (Q3 2026) Earnings Call Highlights: Revenue Tops

PACS Group Inc (NYSE:PACS) reported Q3 2026 revenue growth of 6.4%, with adjusted EBITDA up 33.6% to $175.7M. The company raised full-year guidance, citing strong occupancy and skilled mix improvements. PACS also highlighted a robust acquisition pipeline and integration plans for 31 Eduro facilities. Challenges include lower metrics at newly acquired facilities and ongoing government investigations.

$PACSHigh

Why is PACS stock surging today?

PACS Group Inc (PACS) stock rose 6.0% in after-hours trading after beating Q3 2026 earnings and revenue estimates. The company also raised its full-year 2026 Adjusted EBITDA and revenue guidance. Analysts maintain a 'Moderate Buy' rating with an average price target of $58.80. The surge was driven by company-specific news.